Eagle Pharmaceuticals Inc (EGRX) — Capital Reinvestment Ratio
Eagle Pharmaceuticals Inc (EGRX) has a Capital Reinvestment Ratio of 0.00x as of December 2022, meaning it reinvests 0% of its operating cash flow ($37.56 Million) in capital expenditures ($10.00K). Check EGRX tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Eagle Pharmaceuticals Inc Capital Reinvestment Ratio (2016–2022)
This chart tracks Eagle Pharmaceuticals Inc's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see EGRX cash generation efficiency.
Annual Capital Reinvestment Ratio for Eagle Pharmaceuticals Inc (2016–2022)
Year-by-year Capital Reinvestment Ratio for Eagle Pharmaceuticals Inc from 2016 to 2022. See Eagle Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | $30.80 Million | $178.00K | ▼ -49.5% |
| 2021 | 0.01x | $28.22 Million | $323.00K | ▼ -24.2% |
| 2020 | 0.02x | $49.50 Million | $747.00K | ▲ +8.7% |
| 2019 | 0.01x | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.00x | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.09x | $58.92 Million | $5.19 Million | ▼ -77.4% |
| 2016 | 0.39x | $53.21 Million | $20.69 Million | — |